Arcturus Therapeutics Provides Mid-Year Updates For ARCT-810, Ornithine Transcarbamylase Deficiency And Cystic Fibrosis Programs
Arcturus Therapeutics Provides Mid-Year Updates For ARCT-810, Ornithine Transcarbamylase Deficiency And Cystic Fibrosis Programs
ARCT-810 Phase 2 study completed enrollment at 0.3 mg/kg dose level in Europe with data expected later this year
ARCT-810第二阶段研究已在欧洲完成0.3mg/kg剂量水平的招募，预计今年晚些时候公布数据。
ARCT-810 to expand Phase 2 clinical program in the U.S. to enroll patients with more severe disease
ARCT-810将扩大第二阶段临床计划，招募病情更严重的患者。
ARCT-032 IND for Phase 2 multiple ascending dose study to be submitted in the next 60 days
ARCT-032的第二阶段多剂量上升研究的IND将在接下来的60天内提交。
Arcturus Therapeutics Holdings Inc. ((the "Company", "Arcturus", NASDAQ:ARCT), a global messenger RNA medicines company focused on the development of infectious disease vaccines and medicines to treat unmet medical needs within liver and respiratory rare diseases, today is providing mid-year updates for ARCT-810, an investigational mRNA therapeutic to treat ornithine transcarbamylase (OTC) deficiency, and ARCT-032, an investigational inhaled mRNA therapeutic to treat cystic fibrosis (CF).
Arcturus Therapeutics Holdings Inc.(以下简称“公司”、“Arcturus ”，纳斯达克股票代码：ARCT)是一家全球信使RNA药物公司，致力于开发用于治疗肝脏和呼吸系统中未满足医疗需求的感染性疾病和罕见疾病的疫苗和药物，今天为ARCT-810和ARCT-032提供年中更新。ARCT-810 是一种用于治疗鸟氨酸转移酶缺乏症的mRNA治疗药物，而ARCT-032是一种用于治疗囊性纤维化的mRNA治疗药物。